Abstract
We tested the efficacy of micafungin (FK) alone or in combination with other antifungals against systemic murine aspergillosis. FK alone at 10 mg/kg of body weight/dose prolonged survival (P = 0.01) and reduced CFU in the brain and kidney. Combination therapy that used suboptimal FK with amphotericin B or itraconazole prolonged survival. Although no survivors were free of infection, no antagonism was seen. Nikkomycin Z with FK showed significantly greater potency (P < 0.01) than either alone.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / administration & dosage
-
Animals
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy*
-
Drug Therapy, Combination
-
Echinocandins
-
Female
-
Itraconazole / administration & dosage
-
Lipopeptides
-
Lipoproteins / administration & dosage
-
Lipoproteins / therapeutic use*
-
Micafungin
-
Peptides, Cyclic / administration & dosage
-
Peptides, Cyclic / therapeutic use*
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Lipoproteins
-
Peptides, Cyclic
-
Itraconazole
-
Amphotericin B
-
Micafungin